Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1

Yasuhiko Kamikubo, Ling Zhao, Mark Wunderlich, Takeshi Corpora, R. Katherine Hyde, Thomas A. Paul, Mondira Kundu, Lisa Garrett, Sheila Compton, Gang Huang, Linda Wolff, Yoshiaki Ito, John Bushweller, James C. Mulloy, P. Paul Liu

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Dominant RUNX1 inhibition has been proposed as a common pathway for CBF leukemia. CBFβ-SMMHC, a fusion protein in human acute myeloid leukemia (AML), dominantly inhibits RUNX1 largely through its RUNX1 high-affinity binding domain (HABD). However, the type I CBFβ-SMMHC fusion in AML patients lacks HABD. Here, we report that the type I CBFβ-SMMHC protein binds RUNX1 inefficiently. Knockin mice expressing CBFβ-SMMHC with a HABD deletion developed leukemia quickly, even though hematopoietic defects associated with Runx1-inhibition were partially rescued. A larger pool of leukemia-initiating cells, increased MN1 expression, and retention of RUNX1 phosphorylation are potential mechanisms for accelerated leukemia development in these mice. Our data suggest that RUNX1 dominant inhibition may not be a critical step for leukemogenesis by CBFβ-SMMHC.

Original languageEnglish (US)
Pages (from-to)455-468
Number of pages14
JournalCancer Cell
Volume17
Issue number5
DOIs
StatePublished - May 18 2010

Fingerprint

Leukemia
Acute Myeloid Leukemia
Proteins
Phosphorylation

Keywords

  • CELLCYCLE

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Kamikubo, Y., Zhao, L., Wunderlich, M., Corpora, T., Hyde, R. K., Paul, T. A., ... Liu, P. P. (2010). Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1. Cancer Cell, 17(5), 455-468. https://doi.org/10.1016/j.ccr.2010.03.022

Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1. / Kamikubo, Yasuhiko; Zhao, Ling; Wunderlich, Mark; Corpora, Takeshi; Hyde, R. Katherine; Paul, Thomas A.; Kundu, Mondira; Garrett, Lisa; Compton, Sheila; Huang, Gang; Wolff, Linda; Ito, Yoshiaki; Bushweller, John; Mulloy, James C.; Liu, P. Paul.

In: Cancer Cell, Vol. 17, No. 5, 18.05.2010, p. 455-468.

Research output: Contribution to journalArticle

Kamikubo, Y, Zhao, L, Wunderlich, M, Corpora, T, Hyde, RK, Paul, TA, Kundu, M, Garrett, L, Compton, S, Huang, G, Wolff, L, Ito, Y, Bushweller, J, Mulloy, JC & Liu, PP 2010, 'Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1', Cancer Cell, vol. 17, no. 5, pp. 455-468. https://doi.org/10.1016/j.ccr.2010.03.022
Kamikubo, Yasuhiko ; Zhao, Ling ; Wunderlich, Mark ; Corpora, Takeshi ; Hyde, R. Katherine ; Paul, Thomas A. ; Kundu, Mondira ; Garrett, Lisa ; Compton, Sheila ; Huang, Gang ; Wolff, Linda ; Ito, Yoshiaki ; Bushweller, John ; Mulloy, James C. ; Liu, P. Paul. / Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1. In: Cancer Cell. 2010 ; Vol. 17, No. 5. pp. 455-468.
@article{d98c26a02f834f568c8840181bf925e8,
title = "Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1",
abstract = "Dominant RUNX1 inhibition has been proposed as a common pathway for CBF leukemia. CBFβ-SMMHC, a fusion protein in human acute myeloid leukemia (AML), dominantly inhibits RUNX1 largely through its RUNX1 high-affinity binding domain (HABD). However, the type I CBFβ-SMMHC fusion in AML patients lacks HABD. Here, we report that the type I CBFβ-SMMHC protein binds RUNX1 inefficiently. Knockin mice expressing CBFβ-SMMHC with a HABD deletion developed leukemia quickly, even though hematopoietic defects associated with Runx1-inhibition were partially rescued. A larger pool of leukemia-initiating cells, increased MN1 expression, and retention of RUNX1 phosphorylation are potential mechanisms for accelerated leukemia development in these mice. Our data suggest that RUNX1 dominant inhibition may not be a critical step for leukemogenesis by CBFβ-SMMHC.",
keywords = "CELLCYCLE",
author = "Yasuhiko Kamikubo and Ling Zhao and Mark Wunderlich and Takeshi Corpora and Hyde, {R. Katherine} and Paul, {Thomas A.} and Mondira Kundu and Lisa Garrett and Sheila Compton and Gang Huang and Linda Wolff and Yoshiaki Ito and John Bushweller and Mulloy, {James C.} and Liu, {P. Paul}",
year = "2010",
month = "5",
day = "18",
doi = "10.1016/j.ccr.2010.03.022",
language = "English (US)",
volume = "17",
pages = "455--468",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1

AU - Kamikubo, Yasuhiko

AU - Zhao, Ling

AU - Wunderlich, Mark

AU - Corpora, Takeshi

AU - Hyde, R. Katherine

AU - Paul, Thomas A.

AU - Kundu, Mondira

AU - Garrett, Lisa

AU - Compton, Sheila

AU - Huang, Gang

AU - Wolff, Linda

AU - Ito, Yoshiaki

AU - Bushweller, John

AU - Mulloy, James C.

AU - Liu, P. Paul

PY - 2010/5/18

Y1 - 2010/5/18

N2 - Dominant RUNX1 inhibition has been proposed as a common pathway for CBF leukemia. CBFβ-SMMHC, a fusion protein in human acute myeloid leukemia (AML), dominantly inhibits RUNX1 largely through its RUNX1 high-affinity binding domain (HABD). However, the type I CBFβ-SMMHC fusion in AML patients lacks HABD. Here, we report that the type I CBFβ-SMMHC protein binds RUNX1 inefficiently. Knockin mice expressing CBFβ-SMMHC with a HABD deletion developed leukemia quickly, even though hematopoietic defects associated with Runx1-inhibition were partially rescued. A larger pool of leukemia-initiating cells, increased MN1 expression, and retention of RUNX1 phosphorylation are potential mechanisms for accelerated leukemia development in these mice. Our data suggest that RUNX1 dominant inhibition may not be a critical step for leukemogenesis by CBFβ-SMMHC.

AB - Dominant RUNX1 inhibition has been proposed as a common pathway for CBF leukemia. CBFβ-SMMHC, a fusion protein in human acute myeloid leukemia (AML), dominantly inhibits RUNX1 largely through its RUNX1 high-affinity binding domain (HABD). However, the type I CBFβ-SMMHC fusion in AML patients lacks HABD. Here, we report that the type I CBFβ-SMMHC protein binds RUNX1 inefficiently. Knockin mice expressing CBFβ-SMMHC with a HABD deletion developed leukemia quickly, even though hematopoietic defects associated with Runx1-inhibition were partially rescued. A larger pool of leukemia-initiating cells, increased MN1 expression, and retention of RUNX1 phosphorylation are potential mechanisms for accelerated leukemia development in these mice. Our data suggest that RUNX1 dominant inhibition may not be a critical step for leukemogenesis by CBFβ-SMMHC.

KW - CELLCYCLE

UR - http://www.scopus.com/inward/record.url?scp=77952109450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952109450&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2010.03.022

DO - 10.1016/j.ccr.2010.03.022

M3 - Article

C2 - 20478528

AN - SCOPUS:77952109450

VL - 17

SP - 455

EP - 468

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 5

ER -